ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...

Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

The "Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The ...

In a major advance for breast cancer treatment, AstraZeneca and Daiichi Sankyo announced that their drug DATROWAY ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsRobert DeVitaDavid Hung - Founder, President, CEO ...

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.

The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging.

Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi ...

These pivotal studies investigated AstraZeneca and Daiichi Sankyo’s Enhertu, a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate with a topoisomerase II-targeting ...

Pregnancy and breastfeeding leave behind long-lived CD8+ T cells that can persist for decades, providing lasting immune surveillance in breast tissue.

Daiichi Sankyo (TSE:4568) posted 11.8% earnings growth over the last twelve months, trailing its 32.7% average from the past five years. Net profit margin edged down to 14.1% from 14.2% a year ago.